Jeffrey B Schwimmer1, Joel E Lavine2, Laura A Wilson3, Brent A Neuschwander-Tetri4, Stavra A Xanthakos5, Rohit Kohli5, Sarah E Barlow6, Miriam B Vos7, Saul J Karpen8, Jean P Molleston9, Peter F Whitington10, Philip Rosenthal11, Ajay K Jain12, Karen F Murray13, Elizabeth M Brunt14, David E Kleiner15, Mark L Van Natta3, Jeanne M Clark3, James Tonascia3, Edward Doo16. 1. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California; Department of Gastroenterology, Rady Children's Hospital, San Diego, California. Electronic address: jschwimmer@ucsd.edu. 2. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University, and Morgan Stanley Children's Hospital of New York Presbyterian, New York, New York. 3. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Division of Gastroenterology and Hepatology, St. Louis University, St. Louis, Missouri. 5. Steatohepatitis Center, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 6. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas. 7. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia. 8. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia. 9. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Indiana University School of Medicine/Riley Hospital for Children, Indianapolis, Indiana. 10. Department of Pediatrics, Feinberg Medical School of Northwestern University and the Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois. 11. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, San Francisco Benioff Children's Hospital, San Francisco, California. 12. Department of Pediatrics, St. Louis University, St. Louis, Missouri. 13. Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington School of Medicine and Seattle Children's, Seattle, Washington. 14. Department of Pathology, Washington University in St. Louis, St. Louis, Missouri. 15. National Cancer Institute, Bethesda, Maryland. 16. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
Abstract
BACKGROUND & AIMS: No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD. METHODS: We performed a double-masked trial of 169 children with NAFLD activity scores of 4 or higher at 10 centers. From June 2012 to January 2014, the patients were assigned randomly to receive CBDR or placebo twice daily (300 mg for patients weighing ≤65 kg, 375 mg for patients weighing >65 to 80 kg, and 450 mg for patients weighing >80 kg) for 52 weeks. The primary outcome from the intention-to-treat analysis was improvement in liver histology over 52 weeks, defined as a decrease in the NAFLD activity score of 2 points or more without worsening fibrosis; patients without biopsy specimens from week 52 (17 in the CBDR group and 6 in the placebo group) were considered nonresponders. We calculated the relative risks (RR) of improvement using a stratified Cochran-Mantel-Haenszel analysis. RESULTS: There was no significant difference between groups in the primary outcome (28% of children in the CBDR group vs 22% in the placebo group; RR, 1.3; 95% confidence interval [CI], 0.8-2.1; P = .34). However, children receiving CBDR had significant changes in prespecified secondary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 ± 88 U/L vs 8 ± 77 U/L in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 ± 52 vs 4 ± 36 U/L in the placebo group; P = .008), and a larger proportion had reduced lobular inflammation (36% in the CBDR group vs 21% in the placebo group; RR, 1.8; 95% CI, 1.1-2.9; P = .03). In a post hoc analysis of children weighing 65 kg or less, those taking CBDR had a 4-fold better chance of histologic improvement (observed in 50% of children in the CBDR group vs 13% in the placebo group; RR, 4.0; 95% CI, 1.3-12.3; P = .005). CONCLUSIONS: In a randomized trial, we found that 1 year of CBDR did not reduce overall histologic markers of NAFLD compared with placebo in children. Children receiving CBDR, however, had significant reductions in serum aminotransferase levels and lobular inflammation. ClinicalTrials.gov no: NCT01529268. Copyright Â
RCT Entities:
BACKGROUND & AIMS: No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD. METHODS: We performed a double-masked trial of 169 children with NAFLD activity scores of 4 or higher at 10 centers. From June 2012 to January 2014, the patients were assigned randomly to receive CBDR or placebo twice daily (300 mg for patients weighing ≤65 kg, 375 mg for patients weighing >65 to 80 kg, and 450 mg for patients weighing >80 kg) for 52 weeks. The primary outcome from the intention-to-treat analysis was improvement in liver histology over 52 weeks, defined as a decrease in the NAFLD activity score of 2 points or more without worsening fibrosis; patients without biopsy specimens from week 52 (17 in the CBDR group and 6 in the placebo group) were considered nonresponders. We calculated the relative risks (RR) of improvement using a stratified Cochran-Mantel-Haenszel analysis. RESULTS: There was no significant difference between groups in the primary outcome (28% of children in the CBDR group vs 22% in the placebo group; RR, 1.3; 95% confidence interval [CI], 0.8-2.1; P = .34). However, children receiving CBDR had significant changes in prespecified secondary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 ± 88 U/L vs 8 ± 77 U/L in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 ± 52 vs 4 ± 36 U/L in the placebo group; P = .008), and a larger proportion had reduced lobular inflammation (36% in the CBDR group vs 21% in the placebo group; RR, 1.8; 95% CI, 1.1-2.9; P = .03). In a post hoc analysis of children weighing 65 kg or less, those taking CBDR had a 4-fold better chance of histologic improvement (observed in 50% of children in the CBDR group vs 13% in the placebo group; RR, 4.0; 95% CI, 1.3-12.3; P = .005). CONCLUSIONS: In a randomized trial, we found that 1 year of CBDR did not reduce overall histologic markers of NAFLD compared with placebo in children. Children receiving CBDR, however, had significant reductions in serum aminotransferase levels and lobular inflammation. ClinicalTrials.gov no: NCT01529268. Copyright Â
Authors: Sarah M Lindbäck; Charles Gabbert; Benjamin L Johnson; Emmanuil Smorodinsky; Claude B Sirlin; Natalie Garcia; Perrie E Pardee; Kristin D Kistler; Jeffrey B Schwimmer Journal: Adv Pediatr Date: 2010
Authors: Jeffrey B Schwimmer; Cynthia Behling; Robert Newbury; Reena Deutsch; Caroline Nievergelt; Nicholas J Schork; Joel E Lavine Journal: Hepatology Date: 2005-09 Impact factor: 17.425
Authors: Raj Vuppalanchi; Ajay K Jain; Ross Deppe; Katherine Yates; Megan Comerford; Howard C Masuoka; Brent A Neuschwander-Tetri; Rohit Loomba; Elizabeth M Brunt; David E Kleiner; Jean P Molleston; Jeffrey B Schwimmer; Joel E Lavine; James Tonascia; Naga Chalasani Journal: Clin Gastroenterol Hepatol Date: 2014-05-17 Impact factor: 11.382
Authors: Steven D Stovitz; Jerica M Berge; Rachel J Wetzsteon; Nancy E Sherwood; Peter J Hannan; John H Himes Journal: Child Obes Date: 2014-01-10 Impact factor: 2.992
Authors: Heather M Patton; Katherine Yates; Aynur Unalp-Arida; Cynthia A Behling; Terry T-K Huang; Philip Rosenthal; Arun J Sanyal; Jeffrey B Schwimmer; Joel E Lavine Journal: Am J Gastroenterol Date: 2010-04-06 Impact factor: 10.864
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Jon A Gangoiti; Meredith Fidler; Betty L Cabrera; Jerry A Schneider; Bruce A Barshop; Ranjan Dohil Journal: Br J Clin Pharmacol Date: 2010-09 Impact factor: 4.335
Authors: J Lyons; A Rauh-Pfeiffer; Y M Yu; X M Lu; D Zurakowski; R G Tompkins; A M Ajami; V R Young; L Castillo Journal: Proc Natl Acad Sci U S A Date: 2000-05-09 Impact factor: 11.205
Authors: Mustafa R Bashir; Tanya Wolfson; Anthony C Gamst; Kathryn J Fowler; Michael Ohliger; Shetal N Shah; Adina Alazraki; Andrew T Trout; Cynthia Behling; Daniela S Allende; Rohit Loomba; Arun Sanyal; Jeffrey Schwimmer; Joel E Lavine; Wei Shen; James Tonascia; Mark L Van Natta; Adrija Mamidipalli; Jonathan Hooker; Kris V Kowdley; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2018-10-14 Impact factor: 4.813
Authors: Jonathan A Africa; Cynthia A Behling; Elizabeth M Brunt; Nan Zhang; Yunjun Luo; Alan Wells; Jiayi Hou; Patricia H Belt; Rohit Kohil; Joel E Lavine; Jean P Molleston; Kimberly P Newton; Peter F Whitington; Jeffrey B Schwimmer Journal: Clin Gastroenterol Hepatol Date: 2017-03-07 Impact factor: 11.382
Authors: Kathryn E Harlow; Jonathan A Africa; Alan Wells; Patricia H Belt; Cynthia A Behling; Ajay K Jain; Jean P Molleston; Kimberly P Newton; Philip Rosenthal; Miriam B Vos; Stavra A Xanthakos; Joel E Lavine; Jeffrey B Schwimmer Journal: J Pediatr Date: 2018-04-13 Impact factor: 4.406
Authors: Jonathan R Dillman; Andrew T Trout; Emma N Costello; Suraj D Serai; Kristin S Bramlage; Rohit Kohli; Stavra A Xanthakos Journal: AJR Am J Roentgenol Date: 2017-10-18 Impact factor: 3.959
Authors: Jeffrey B Schwimmer; Patricia Ugalde-Nicalo; Jean A Welsh; Jorge E Angeles; Maria Cordero; Kathryn E Harlow; Adina Alazraki; Janis Durelle; Jack Knight-Scott; Kimberly P Newton; Rebecca Cleeton; Cynthia Knott; Juna Konomi; Michael S Middleton; Curtis Travers; Claude B Sirlin; Albert Hernandez; Ahlia Sekkarie; Courtney McCracken; Miriam B Vos Journal: JAMA Date: 2019-01-22 Impact factor: 56.272